Grimes & Company, Inc. Adma Biologics, Inc. Transaction History

Grimes & Company, Inc.

$3.93 Billion
Q3 2025

A detailed history of Grimes & Company, Inc. transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Grimes & Company, Inc. holds 13,674 shares of ADMA stock, worth $202,922. This represents 0.01% of its overall portfolio holdings.

Number of Shares

13,674

Previous 13,674 -0.0%

Holding current value

$202,922

Previous $249,000 19.68%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 22, 2025	SELL	$17.6 - $24.51 $141,081 - $196,472	-8,016 Reduced 36.96%	13,674 $249,000
Q1 2025 Apr 17, 2025	SELL	$15.44 - $20.61 $17,323 - $23,124	-1,122 Reduced 4.92%	21,690 $430,000
Q4 2024 Jan 21, 2025	SELL	$15.62 - $22.62 $7,388 - $10,699	-473 Reduced 2.03%	22,812 $391,000
Q3 2024 Oct 22, 2024	SELL	$11.21 - $20.03 $187,229 - $334,541	-16,702 Reduced 41.77%	23,285 $465,000
Q2 2024 Jul 22, 2024	SELL	$5.98 - $11.18 $31,574 - $59,030	-5,280 Reduced 11.66%	39,987 $447,000
Q1 2023 Apr 20, 2023	SELL	$3.01 - $3.87 $24,221 - $31,141	-8,047 Reduced 15.09%	45,267 $149,000
Q1 2022 May 06, 2022	SELL	$1.28 - $1.83 $1,116 - $1,595	-872 Reduced 1.61%	53,314 $98,000
Q2 2021 Aug 04, 2021	BUY	$1.51 - $2.07 $4,705 - $6,450	3,116 Added 6.1%	54,186 $87,000
Q1 2021 May 12, 2021	BUY	$1.67 - $2.95 $26,320 - $46,494	15,761 Added 44.64%	51,070 $90,000
Q4 2020 Feb 02, 2021	BUY	$1.8 - $2.56 $3,256 - $4,631	1,809 Added 5.4%	35,309 $69,000
Q3 2020 Nov 12, 2020	BUY	$2.04 - $3.74 $68,340 - $125,290	33,500 New	33,500 $80,000

Others Institutions Holding ADMA

# of Institutions

391

Shares Held

190M

Call Options Held

2.08M

Put Options Held

1.56M

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $2.91B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Grimes & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Grimes & Company, Inc. with notifications on news.

Account

Grimes & Company, Inc. Adma Biologics, Inc. Transaction History